Rilmenidine

Rilmenidine

SCHEMBL30892124

C1COC(NC(C2CC2)C2CC2)=N1.O=C(O)/C=C/C(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

NISCH

The experimentally established mechanism targets of Rilmenidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NISCH known ✓ Q9Y2I1 3/20 0.73
CYP3A4 P08684 2/20 1.00
POLB P06746 2/20 1.00
KDM4E B2RXH2 1/20 1.00
MAPT P10636 1/20 1.00
NFKB1 P19838 1/20 1.00
ADRA2A P08913 10/20 0.73
ADRA2B P18089 10/20 0.73
ADRA2C P18825 9/20 0.73
ADRA1A P35348 3/20 0.73
GMNN O75496 1/20 0.73
CYP1A2 P05177 1/20 0.73
HTR1A P08908 1/20 0.73
CYP2D6 P10635 1/20 0.73
CYP2C9 P11712 1/20 0.73
TSHR P16473 1/20 0.73
OPRK1 P41145 1/20 0.73
HIF1A Q16665 1/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Rilmenidine SCHEMBL114420 0.86 ADRA2A (1.00) CYP3A4POLBKDM4EMAPTNFKB1
SCHEMBL6368709 0.78 ADRA2A (0.83) CYP3A4POLBKDM4EMAPTNFKB1
Rilmenidine SCHEMBL6373730 0.73 ADRA2A (0.73) CYP3A4POLBKDM4EMAPTNFKB1
Fumaric Acid SCHEMBL11639828 0.71 NFKB1 (0.55) CYP3A4POLBKDM4EMAPTNFKB1
SCHEMBL11668019 0.67 ADRA2A (0.64) CYP3A4POLBKDM4EMAPTNFKB1
SCHEMBL11140750 0.66 ADRA2A (0.62) CYP3A4POLBKDM4EMAPTNFKB1
SCHEMBL6369410 0.63 ADRA2A (0.57) CYP3A4POLBKDM4EMAPTNFKB1
SCHEMBL6367795 0.63 ADRA2A (0.57) CYP3A4POLBKDM4EMAPTNFKB1
SCHEMBL6367792 0.63 ADRA2A (0.57) CYP3A4POLBKDM4EMAPTNFKB1
SCHEMBL12870235 0.62

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240299391-A1 COMPOUNDS AND METHODS FOR TREATMENT OF DIAMOND BLACKFAN ANEMIA THE CHILDREN'S MEDICAL CENTER CORPORATION (US) 2024-09-12 US disclosed
US-11980620-B2 Compounds and methods for treatment of Diamond Blackfan anemia THE CHILDREN'S MEDICAL CENTER CORPORATION (US) 2024-05-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240299391-A1 COMPOUNDS AND METHODS FOR TREATMENT OF DIAMOND BLACKFAN ANEMIA RPS3A, BECN1, RPS2 NISCH 3410/4885CYP3A4 4519/4885POLB 1044/4885
US-11980620-B2 Compounds and methods for treatment of Diamond Blackfan anemia RPS3A, BECN1, RPS2 NISCH 3410/4885CYP3A4 4519/4885POLB 1044/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.